EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Eosinophil Dynamics May Help Differentiate Immune‐Related From TKI ‐Related Adverse Events During IO – TKI Therapy for Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study

Misato Tomita, Yoshihiko Tasaki iD, Shuzo Hamamoto iD, Takahiro Osawa iD, Shimpei Yamashita iD, Ryuji Matsumoto iD, Hiroaki Ikoma, Kengo Kawase iD, Yoshihisa Mimura iD, Yosuke Sugiyama iD, Takahiro Yasui iD, Yoko Furukawa-Hibi iD

Cancer Medicine · 2026

DOI: 10.1002/cam4.72422 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Misato Tomita und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Eosinophils, Kidney Neoplasms, Protein Kinase Inhibitors. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Combination therapy with immune checkpoint inhibitors and tyrosine kinase inhibitors (IO–TKI) is a key treatment option for metastatic renal cell carcinoma (mRCC), but distinguishing immune‐related adverse events (irAEs) from TKI‐related adverse events (TKI‐AEs) is challenging because of overlapping clinical features. We aimed to evaluate whether eosinophil counts can help differentiate between them.

Methods

In this retrospective multicenter study, 123 patients with mRCC treated with IO–TKI therapy were analyzed. Patients were classified into an irAE group ( n = 64) and a TKI‐AE group ( n = 59). Changes in eosinophil counts from baseline to the start of the second treatment cycle were compared. Receiver operating characteristic (ROC) and logistic regression analyses were performed to assess associations with irAE occurrence.

Results

Baseline eosinophil counts did not differ between groups. Eosinophil counts at the start of the second treatment cycle were higher in the irAE group than those in the TKI‐AE group (269.6 vs. 189.6 eosinophils/μL; p < 0.05). No significant differences were observed in other blood parameters, including neutrophil, lymphocyte, monocyte, and platelet counts, the neutrophil‐to‐lymphocyte ratio, or the platelet‐to‐lymphocyte ratio. Although the overall discriminatory performance was modest (area under the ROC curve = 0.57, sensitivity = 0.30, specificity = 0.94), eosinophil counts ≥ 380/μL were associated with irAEs in both univariate (odds ratio = 7.21) and multivariable (odds ratio = 8.39; p < 0.05) analyses.

Conclusions

Early increases in eosinophil counts were associated with irAEs and may help distinguish irAEs from TKI‐AEs during IO–TKI therapy. Given their high specificity but limited sensitivity, eosinophil counts may have utility as an adjunctive rather than stand‐alone marker, and prospective validation is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellEosinophilsKidney NeoplasmsProtein Kinase InhibitorsImmune Checkpoint InhibitorsDrug-Related Side Effects and Adverse ReactionsHumansRetrospective StudiesFemaleMaleMiddle AgedAgedLeukocyte CountROC Curve

Stichwörter der Autor:innen

biomarkereosinophilimmune checkpoint inhibitorsimmune‐related adverse eventsrenal cell carcinomatyrosine kinase inhibitors

Substanzen

Protein Kinase InhibitorsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Urology and Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Department of Urology, Wakayama Medical University, Wakayama, Japan.
  • Department of Urology, Hokkaido University, Sapporo, Japan.

ORCID-Profile: Yoshihiko Tasaki, Shuzo Hamamoto, Takahiro Osawa, Shimpei Yamashita, Ryuji Matsumoto, Kengo Kawase, Yoshihisa Mimura, Yosuke Sugiyama, Takahiro Yasui, Yoko Furukawa-Hibi

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Tomita, M., Tasaki, Y., Hamamoto, S., Osawa, T., Yamashita, S., Matsumoto, R., Ikoma, H., Kawase, K., Mimura, Y., Sugiyama, Y., Yasui, T., & Furukawa-Hibi, Y. (2026). Eosinophil Dynamics May Help Differentiate Immune‐Related From TKI ‐Related Adverse Events During IO – TKI Therapy for Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study. Cancer Medicine. https://doi.org/10.1002/cam4.72422

Vancouver

Tomita M, Tasaki Y, Hamamoto S, Osawa T, Yamashita S, Matsumoto R, et al. Eosinophil Dynamics May Help Differentiate Immune‐Related From TKI ‐Related Adverse Events During IO – TKI Therapy for Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study. Cancer Medicine. 2026. doi:10.1002/cam4.72422

BibTeX
@article{Tomita2026,
  author = {Tomita, Misato and Tasaki, Yoshihiko and Hamamoto, Shuzo and Osawa, Takahiro and Yamashita, Shimpei and Matsumoto, Ryuji and Ikoma, Hiroaki and Kawase, Kengo and Mimura, Yoshihisa and Sugiyama, Yosuke and Yasui, Takahiro and Furukawa-Hibi, Yoko},
  title = {Eosinophil Dynamics May Help Differentiate Immune‐Related From TKI ‐Related Adverse Events During IO – TKI Therapy for Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72422}
}
Kostenlos starten →